Covaxin phase 2 trials show vaccine safe, induces immune response
The Hindu
India's first indigenous vaccine against COVID-19, Covaxin, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.
The authors of the study noted that the phase 2 results did not asses the efficacy of the vaccine codenamed BBV152.
More Related News

“I’ve never even been to these places before,” she laughed, “and suddenly I have memories in all of them.” The dates, she added, were genuinely good — long walks, easy conversations, and meals that stretched late into the evening — and the best part was that none of it felt heavy. The boys she met are all planning to visit her in Mumbai soon, not under without any pressure but with a sense of pleasant continuity. “I’m great,” she said, and she meant it.











